World Market for Psychotherapeutic Drugs Closes in on $50 Billion in Sales

     World Market for Psychotherapeutic Drugs Closes in on $50 Billion in
Sales

     NEW YORK, Jan. 18 /PRNewswire/ -- Based on the steadily increasing
     success of current drugs on the market as well as the potential
success of
     numerous drugs currently in late stage development or awaiting
regulatory
     approval, sales of psychotherapeutic drugs treating everything from
     schizophrenia and depression to ADHD and anxiety are expected to reach
     nearly $50 billion by 2010, according to a new report from life
science
     research firm Kalorama Information.
         The World Market for Psychotherapeutic Drugs, the most exhaustive
guide
     to this booming market, shows 2005 revenues checking in at $35.7
billion,
     up 3.9% over 2004. The report anticipates new products bringing in an
     additional $6.3 billion by 2010 increasing the competitive outlook in
many
     segments.
         Antipsychotics and antimanics along with antidepressants make up
the
     lions share of worldwide sales accounting for nearly 80% of the
market.
     Sales of antianxiety drugs, ADHD stimulants and nonstimulants, and
other
     psychotherapeutic drugs segments rounded out the mix of remedies to
treat a
     remarkably under-treated global incidence of mental illness.
         In fact, the U.S. accounts for more than 62% of worldwide sales as
in
     many parts of the world there is still a negative view and stigma
     surrounding mental health issues. In contrast, Japan accounts for only
2%
     of global sales.
         "The potential market is definitely worth billions more than the
     current market where many regions suffer from a lack of education,
mental
     health policy, and services to evaluate and treat mental health
patients,"
     notes Melissa Elder, the report's author. "Despite these global
     inadequacies, there are extremely promising drugs in the pipeline that
     should have a tremendous impact on this industry within the next few
     years."
         The World Market for Psychotherapeutic Drugs provides a historical
     market overview, including condition statistics and market forecasts
for
     each of the major psychotherapeutic segments. It also includes
in-depth
     company profiles of emerging competitors and leaders in the field, and
     profiles of drugs in the pipeline with expected approval status and
     implications for their impact on the market. It can be purchased
directly
     from Kalorama Information by visiting
     http://www.kaloramainformation.com/Psychotherapeutic-Drugs-1340128. It
is
     also available at MarketResearch.com.
         About Kalorama Information
         Kalorama Information, a division of MarketResearch.com, supplies
the
     latest in independent market research for the life sciences. For more
     information, contact Tom Ehart at 240-747-3014 or
     tehart@marketresearch.com, or visit
http://www.KaloramaInformation.com.